Quinoline compounds and their use for treating viral infection

A method for treating an infection with a virus, comprising administering to a subject in need thereof an effective amount of a compound of formula (I):

• wherein A is N;
• each of B, D, E, F, and G, independently, is CR, R being H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted aryl, optionally substituted heteroaryl, halo, nitro, cyano, amino, hydroxy, alkoxy, aryloxy, C(O)Ra, C(O)ORa, C(O)NRaRb, C(S)Ra, C(NRa)Rb, NRaRb, or NRaCONRbRc, in which each of Ra, Rb, and Rc, independently, is H, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, aryloxy, amino, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl;
• R1 is alkoxy, C(O)Rd, C(O)ORd, CONRdRe, SO2Rd, or CN, in which each of Rd and Re, independently, is H, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, aryloxy, amino, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl;
• each of R2 and R3, independently, is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted aryl, optionally substituted heteroaryl, halo, nitro, cyano, amino, hydroxy, alkoxy, aryloxy, C(O)Rf, C(O)ORf, C(O)NRfRg, C(S)Rf, C(NRf)Rg, NRfRg, or NRfCONRgRh, in which each of Rf, Rg, and Rh, independently, is H, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, aryloxy, amino, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl;
• X is
• Y is arylene or a heteroarylene having 1-4 heteroatoms independently selected from the group consisting of N, S, and O;
• n is 0, 1, 2, 3, 4, or 5;
• p is 1, 2, 3, or 4;
• and
• q is 0, 1, 2, 3, 4, 5, 6, or 7.

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula (I):

• wherein A is N;
• each of B, D, E, F, and G, independently, is CR, R being H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted aryl, optionally substituted heteroaryl, halo, nitro, cyano, amino, hydroxy, alkoxy, aryloxy, C(O)Ra, C(O)ORa, C(O)NRaRb, C(S)Ra, C(NRa)Rb, NRaRb, or NRaCONRbRc, in which each of Ra, Rb, and Rc, independently, is H, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, aryloxy, amino, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl;
• R1 is alkoxy, C(O)Rd, C(O)ORd, CONRdRe, SO2Rd, or CN, in which each of Rd and Re, independently, is H, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, aryloxy, amino, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl;
• each of R2 and R3, independently, is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted aryl, optionally substituted heteroaryl, halo, nitro, cyano, amino, hydroxy, alkoxy, aryloxy, C(O)Rf, C(O)ORf, C(O)NRfRg, C(S)Rf, C(NRf)Rg, NRfRg, or NRfCONRgRh, in which each of Rf, Rg, and Rh, independently, is H, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, aryloxy, amino, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl;
• X is
• Y is arylene or a heteroarylene having 1-4 heteroatoms independently selected from the group consisting of N, S, and O;
• n is 0, 1, 2, 3, 4, or 5;
• p is 1, 2, 3, or 4;
• and
• q is 0, 1, 2, 3, 4, 5, 6, or 7.